| |
| |
|
| Insider
Information: |
Ratcliffe Liam |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
14 |
|
| Direct
Shares |
5,450,392 |
|
|
Indirect Shares
|
11,059,115 |
|
|
| Direct
Value |
$32,791,673 |
|
|
|
Indirect Value
|
$72,584,031 |
|
|
| Total
Shares |
16,509,507 |
|
|
| Total
Value |
$105,375,705 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
11
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
1
|
11
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-11.0
|
| Percentage
Gain/Loss : |
 11.6%
|
 -418.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Relypsa Inc |
RLYP |
Former 10% beneficial ... |
2013-11-20 |
0 |
2013-11-20 |
2,114,890 |
Premium* |
|
|
Oxford Immunotec Global Plc |
OXFD |
10% Owner |
2013-11-21 |
1,377,497 |
|
0 |
Premium* |
|
|
MEI Pharma Inc |
MEIP |
10% Owner |
2015-03-24 |
0 |
2013-11-21 |
0 |
Premium* |
|
|
Concert Pharmaceuticals, Inc. |
CNCE |
10% Owner |
2014-02-19 |
107,327 |
|
0 |
Premium* |
|
|
Chimerix Inc |
CMRX |
10% Owner |
2014-03-18 |
1,543,394 |
2014-03-18 |
0 |
Premium* |
|
|
Aravive Inc |
ARAV |
10% Owner |
2014-12-18 |
2,409,374 |
2014-03-27 |
0 |
Premium* |
|
|
Durata Therapeutics, Inc. |
DRTX |
10% Owner |
2014-11-17 |
0 |
2014-11-17 |
0 |
Premium* |
|
|
Cogent Biosciences, Inc. |
COGT |
Director |
2018-04-03 |
0 |
2018-04-03 |
897,773 |
Premium* |
|
|
Deciphera Pharmaceuticals, Inc. |
DCPH |
Director, 10% Owner |
2017-10-02 |
0 |
2017-10-02 |
2,146,308 |
Premium* |
|
|
Iterum Therapeutics Plc |
ITRM |
10% Owner |
2018-05-30 |
0 |
2018-05-30 |
384,615 |
Premium* |
|
|
Aptinyx Inc. |
APTX |
Director, 10% Owner |
2018-06-25 |
0 |
2018-06-25 |
368,345 |
Premium* |
|
|
Arvinas Holding Company, Llc |
ARVN |
Director |
2021-11-05 |
0 |
2021-12-16 |
185,686 |
Premium* |
|
|
PDS Biotechnology Corp |
PDSB |
Director |
2019-03-15 |
10,000 |
2019-03-15 |
2,344,868 |
Premium* |
|
|
Passage Bio, Inc. |
PASG |
Director |
2020-03-03 |
2,800 |
2020-03-03 |
2,616,630 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
47 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| OXFD |
Oxford Immunotec Global P... |
10% Owner |
– – • |
2013-11-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,377,497 |
|
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
10% Owner |
– – • |
2014-02-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,291 |
|
- |
|
| RLYP |
Relypsa Inc |
Former 10% beneficial owner |
– – – |
2013-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
1,924,626 |
1,924,626 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
10% Owner |
– – • |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
92,036 |
107,327 |
0 |
- |
|
| CMRX |
Chimerix Inc |
10% Owner |
– – • |
2014-03-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(700,000) |
1,543,394 |
0 |
- |
|
| ARAV |
Aravive Inc |
10% Owner |
– – • |
2014-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
3,311,930 |
3,311,930 |
0 |
- |
|
| DRTX |
Durata Therapeutics, Inc. |
10% Owner |
– – • |
2014-11-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,028,439) |
0 |
0 |
- |
|
| DCPH |
Deciphera Pharmaceuticals... |
Director |
– • • |
2017-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,729,140 |
1,771,308 |
0 |
- |
|
| COGT |
Cogent Biosciences, Inc. |
Director |
– • – |
2018-04-03 |
4 |
A |
$0.00 |
$0 |
I/I |
1,245,545 |
622,773 |
0 |
- |
|
| ITRM |
Iterum Therapeutics Plc |
10% Owner |
– – • |
2018-05-30 |
4 |
A |
$0.00 |
$0 |
I/I |
793,626 |
793,626 |
0 |
- |
|
| APTX |
Aptinyx Inc. |
Director |
– • • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,040,079 |
243,345 |
0 |
- |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,283,048 |
1,283,048 |
0 |
- |
|
| PDSB |
PDS Biotechnology Corp |
Director |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| PASG |
Passage Bio, Inc. |
Director |
– • – |
2020-03-03 |
4/A |
A |
$0.00 |
$0 |
I/I |
2,066,630 |
2,066,630 |
0 |
- |
|
| MEIP |
MEI Pharma Inc |
10% Owner |
– – • |
2015-03-24 |
4 |
S |
$1.97 |
$3,160,183 |
D/D |
(1,601,390) |
0 |
0 |
- |
|
| MEIP |
MEI Pharma Inc |
10% Owner |
– – • |
2014-12-09 |
4 |
S |
$6.01 |
$421,082 |
D/D |
(70,081) |
1,601,390 |
0 |
- |
|
| MEIP |
MEI Pharma Inc |
10% Owner |
– – • |
2014-12-08 |
4 |
S |
$6.05 |
$54,495 |
D/D |
(9,004) |
1,671,471 |
0 |
- |
|
| MEIP |
MEI Pharma Inc |
10% Owner |
– – • |
2013-11-21 |
4 |
S |
$8.25 |
$3,011,250 |
D/D |
(365,000) |
1,680,475 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Former 10% beneficial owner |
– – – |
2013-11-20 |
4 |
OE |
$9.18 |
$238,594 |
I/I |
25,977 |
1,950,603 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Former 10% beneficial owner |
– – – |
2013-11-20 |
4 |
D |
$11.00 |
$238,601 |
I/I |
(21,691) |
1,928,912 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Former 10% beneficial owner |
– – – |
2013-11-20 |
4 |
B |
$11.00 |
$2,045,758 |
I/I |
185,978 |
2,114,890 |
0.01 |
- |
|
| COGT |
Cogent Biosciences, Inc. |
Director |
– • – |
2018-04-03 |
4 |
B |
$12.00 |
$6,600,000 |
I/I |
550,000 |
897,773 |
2.1 |
- |
|
| ITRM |
Iterum Therapeutics Plc |
10% Owner |
– – • |
2018-05-30 |
4 |
B |
$13.00 |
$8,614,801 |
I/I |
662,677 |
384,615 |
1.5 |
- |
|
| APTX |
Aptinyx Inc. |
Director |
– • • |
2018-06-25 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
368,345 |
2.25 |
- |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2018-10-01 |
4 |
B |
$16.00 |
$16,000,000 |
I/I |
1,000,000 |
375,000 |
2.1 |
- |
|
47 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
